1. **DISCUSSION:** Please discuss whether there are sufficient data to support a finding that oxycodone hydrochloride immediate-release tablets (MNK-812) has properties that can be expected to deter abuse, commenting on support for abuse-deterrent effects for each of the following routes of abuse:

   a. Nasal
   b. Intravenous

2. **DISCUSSION:** The Applicant is requesting approval of oxycodone hydrochloride immediate-release tablets (MNK-812) as an analgesic with properties expected to deter abuse by the intravenous and intranasal routes. Discuss whether you have any concerns regarding the impact of this oxycodone hydrochloride immediate-release product (MNK-812) on public health. Take into consideration its potential effect on the abuse of opioids, including oxycodone, as well as potential consequences of administration of this product by unintended routes.

3. **VOTE:** If approved, should oxycodone hydrochloride immediate-release tablets (MNK-812) be labeled as an abuse-deterrent product by the nasal route of abuse?

4. **VOTE:** If approved, should oxycodone hydrochloride immediate-release tablets (MNK-812) be labeled as an abuse-deterrent product by the intravenous route of abuse?

5. **VOTE:** Should oxycodone hydrochloride immediate-release tablets (MNK-812) be approved for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate?